GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (NYSE:PRGO) » Definitions » Net Income From Continuing Operations

Perrigo Co (Perrigo Co) Net Income From Continuing Operations

: $-13 Mil (TTM As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Perrigo Co's net income from continuing operations for the three months ended in Dec. 2023 was $-32 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-13 Mil.


Perrigo Co Net Income From Continuing Operations Historical Data

The historical data trend for Perrigo Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 146.10 -162.60 -68.90 -140.60 -12.70

Perrigo Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income From Continuing Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.70 -3.00 8.40 14.20 -32.30

Perrigo Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perrigo Co (Perrigo Co) Business Description

Industry
Traded in Other Exchanges
Address
The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Executives
Robert Willis officer: Acting CHRO C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Alison Ives officer: EVP & Chief Scientific Officer C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Eduardo Guarita Bezerra officer: EVP & Chief Financial Officer C/O FRESH DEL MONTE PRODUCE INC., PO BOX 149222, CORAL GABLES FL 33134
Patrick Lockwood-taylor director, officer: CEO C/O PERRIGO COMPANY PLC, 430 MONROE AVE NW, GRAND RAPIDS MI 49503
Julia M Brown director C/O ABLE BRANDS CO., 30 HUDSON YARDS, NEW YORK NY 10001
Triona Schmelter officer: EVP & President CSCA 2021 SPRING ROAD, SUITE 600, OAK BROOK IL 60523
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Svend Andersen director C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Murray S Kessler director, officer: CEO 714 GREEN VALLEY ROAD, GREENSBORO NC 27408
Thomas Farrington officer: Senior VP and CIO 4012 W. CANTERBURY CT., NEQUON WI 53092
Dillard James E Iii officer: EVP, Chief Scientific Officer 6601 WEST BROAD STREET, RICHMOND VA 23230
Ronald Craig Janish officer: EVP, Global Op. & Supply Chain PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Grainne Quinn officer: EVP, Chief Medical Officer PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Albert Manzone director C/O MERISANT, AVENUE JEAN-JACQUES ROUSSEAU 7, NEUCHATEL V8 CH-2000
Kyle Hanson officer: EVP & General Counsel